-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KyDv2W7fOqaoIQeBNK+1vvQA4r3s4Vcn3PC6XJuSxGWgvwYz8zafzIAI6ESK61gK jsm2EugvsZE3mfludGXejQ== 0000950116-00-000946.txt : 20000425 0000950116-00-000946.hdr.sgml : 20000425 ACCESSION NUMBER: 0000950116-00-000946 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20000424 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BOVIE MEDICAL CORP CENTRAL INDEX KEY: 0000719135 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL ORGANIC CHEMICALS [2860] IRS NUMBER: 112644611 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: SEC FILE NUMBER: 005-35626 FILM NUMBER: 607264 BUSINESS ADDRESS: STREET 1: 734 WALT WHITMAN ROAD CITY: MELVILLE STATE: NY ZIP: 11747 BUSINESS PHONE: 5164215452 MAIL ADDRESS: STREET 1: 734 WALT WHITMAN ROAD CITY: MELVILLE STATE: NY ZIP: 11747 FORMER COMPANY: FORMER CONFORMED NAME: AN CON GENETICS INC DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: HERRICK FEINSTEIN LLP /FA CENTRAL INDEX KEY: 0001016570 STANDARD INDUSTRIAL CLASSIFICATION: [] STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: 2 PARK AVENUE 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 2125921491 MAIL ADDRESS: STREET 1: 2 PARK AVENUE CITY: NEWYORK STATE: NY ZIP: 10016 SC 13D 1 SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 3 )* BOVIE MEDICAL CORPORATION - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock - -------------------------------------------------------------------------------- (Title of Class of Securities) 10211F 10 0 -------------------------- (CUSIP Number) Mr. Eric Rainer Bashford Irwin A. Kishner, Esq. 2689 Strang Boulevard Herrick, Feinstein LLP Yorktown Heights, New York 10598 2 Park Avenue Tel.: (914) 572-4327 New York, New York 10016 Tel.: (212) 592-1400 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) April 12, 2000 ------------------------------ (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box / /. *The remainder of this cover page shall be filed out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). (Continued on following page(s)) Page 1 of 4 Pages - -------------------------------------------------------------------------------- CUSIP NO. 10211F100 13D Page 2 of 4 Pages - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Eric Rainer Bashford Charitable Remainder Unitrust - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / / (b) / / - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) / / - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 779,000 ------------------------------------------------- NUMBER OF 8 SHARED VOTING POWER SHARES BENEFICIALLY -0- OWNED BY ------------------------------------------------- EACH 9 SOLE DISPOSITIVE POWER REPORTING PERSON 779,000 WITH ------------------------------------------------- 10 SHARED DISPOSITIVE POWER -0- - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 779,000 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / / - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 5.59% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* - -------------------------------------------------------------------------------- * SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION Page 3 of 4 Pages PART II TO SCHEDULE 13D This statement constitutes Amendment No. 3 to the statement on Schedule 13D filed with the Securities and Exchange Commission on February 19, 1998 (the "Original Statement"). All defined terms hereunder have the meanings set forth in the Original Statement. This Amendment No. 3 reflects certain material changes in the information set forth in the Original Statement, as amended as of March 10, 1999 and as of March 16, 2000, as follows: Item 1. Security and Issuer ------------------- Shares of Common Stock Bovie Medical Corporation 734 Walt Whitman Road Suite 207 Melville, New York 11747 (hereinafter, the "Issuer") ------ Item 5. Interest in Securities of the Issuer ------------------------------------ (a) Prior to April 12, 2000, the Trust was the beneficial owner of 904,000 shares of Common Stock of the Issuer (the "Trust Shares"), representing 6.49% of the Issuer's Common Stock. The Trust sold 125,000 of the Trust Shares described in item 5(c) below. (c) The Trust sold 125,000 shares of the Issuer's Common Stock for cash in a private securities transaction at a price per share equal to $0.16. Item 6. Contracts, Arrangements, Understandings of Relationships With Respect to Securities of the Issuer --------------------------------------------------------------------- None. Item 7. Exhibits -------- None. Page 4 of 4 Pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. By: /s/ Eric Rainer Bashford - ------------------------------------ ----------------------------- Date Eric Rainer Bashford -----END PRIVACY-ENHANCED MESSAGE-----